SCHEMBL6780790

SCHEMBL6780790

CCOC(=O)c1cn2c3c(cc(CN4CCOCC4)cc3c1=O)OC(c1cccc(COCOC)c1)C2

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.37
ALDH1A1 P00352 6/20 0.36
POLA1 P09884 1/20 0.35
LMNA P02545 4/20 0.35
HSD17B10 Q99714 3/20 0.35
TSHR P16473 3/20 0.35
MAPT P10636 1/20 0.35
MAPK1 P28482 1/20 0.35
STAT3 P40763 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 2/20 0.35
KDM4E B2RXH2 2/20 0.34
HPGD P15428 1/20 0.34
KMT2A Q03164 1/20 0.32
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6776971 0.88 ALDH1A1 (0.45) RXFP1ALDH1A1POLA1LMNAHSD17B10
SCHEMBL6781745 0.86 MAPT (0.33) RXFP1ALDH1A1LMNAHSD17B10TSHR
SCHEMBL6777893 0.85 MAPT (0.32) RXFP1LMNATSHRMAPTKMT2A
SCHEMBL6700057 0.85 POLA1 (0.55) ALDH1A1POLA1TSHRKMT2AKCNH2
SCHEMBL6780920 0.83 RXFP1 (0.36) RXFP1ALDH1A1POLA1LMNAHSD17B10
SCHEMBL6699708 0.79 POLA1 (0.46) ALDH1A1POLA1LMNATSHRRAB9A
SCHEMBL6700840 0.78 POLA1 (0.57) ALDH1A1POLA1TSHRRAB9AKMT2A
SCHEMBL6781920 0.76 ALDH1A1 (0.39) ALDH1A1POLA1LMNAHSD17B10TSHR
SCHEMBL6413852 0.75 ALDH1A1 (0.44) ALDH1A1POLA1LMNAHSD17B10TSHR
SCHEMBL6702306 0.73 POLA1 (0.55) ALDH1A1POLA1TSHRKMT2AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1299395-B1 OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS UPJOHN CO (US) 2004-09-15 EP disclosed
US-6673793-B2 N-(4-CHLOROBENZYL)-9-(MORPHOLIN-4-YLMETHYL)-7-OXO-2-(S)-PYRIDIN-2-YL-2,3-DIHYDRO-7H-(1,4) OXAZINO(2,3,4-IJ)QUINOLINE-6-CARBOXAMIDE, FOR EXAMPLE; INHIBITING A VIRAL DNA POLYMERASE; TREATING VIRUSES OF HERPES FAMILY PHARMACIA & UPJOHN CO. 2004-01-06 US disclosed
EP-1299395-A1 OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 2003-04-09 EP disclosed
US-20020103170-A1 Oxazinoquinolones useful for the treatment of viral infections PHARMACIA & UPJOHN COMPANY 2002-08-01 US disclosed
WO-2002004462-A1 OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 2002-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103170-A1 Oxazinoquinolones useful for the treatment of viral infections ZC3HAV1, RPL5, ZC3HAV1L RXFP1 4210/4885ALDH1A1 594/4885POLA1 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.